Evidence map›Paper›PMID 41318530›Full record

Reviewnpj aging2025

Microglial lipid droplets as therapeutic targets in age-related neurodegenerative diseases.

Soyoung Sung, Hui-Ju Kim, Sun Joo Cha, Minyeop Nahm, Seung Hyun Kim, Min-Soo Kwon

Abstract readReview
In one paragraph

Review in npj aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Circular RNAEnvironment & health (Washington, D.C.) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. bioRxiv : the preprint server for biology · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Soyoung Sung *Department of Pharmacology, Research Institute of Basic Medical Science, School of Medicine, CHA University, CHA BIO COMPLEX, Seongnam-si, Gyeonggi-do, Republic of Korea.
Hui-Ju Kim *Department of Pharmacology, Research Institute of Basic Medical Science, School of Medicine, CHA University, CHA BIO COMPLEX, Seongnam-si, Gyeonggi-do, Republic of Korea.
Sun Joo ChaDementia Research Group, Korea Brain Research Institute, Daegu, Republic of Korea.
Minyeop NahmDementia Research Group, Korea Brain Research Institute, Daegu, Republic of Korea.
Seung Hyun KimDepartment of Neurology, College of Medicine, Hanyang University, Seoul, Republic of Korea.
Min-Soo KwonDepartment of Pharmacology, Research Institute of Basic Medical Science, School of Medicine, CHA University, CHA BIO COMPLEX, Seongnam-si, Gyeonggi-do, Republic of Korea. minsoo100@cha.ac.kr.

Funding

National Research Foundation of Korea 2023R1A2C1006622
6 · The paper itself

Abstract

Monoclonal antibodies approved for Alzheimer's disease (AD), such as lecanemab and aducanumab, have been shown to enhance microglial phagocytic function, underscoring the therapeutic relevance of microglia in neurodegenerative diseases (NDDs). Emerging evidence implicates lipid droplets (LDs) in brain aging and NDDs, particularly through LDs-laden microglia known as lipid droplet-accumulating microglia (LDAM), which exhibit impaired phagocytosis, elevated oxidative stress, and dysregulated lipid metabolism. Among microglial subtypes identified through transcriptomic and functional profiling-including disease-associated microglia (DAM), microglia in neurodegenerative disease (MGnD), white matter-associated microglia (WAM), and dark microglia-LDs-laden microglia have clear metabolic signatures defined by excessive LDs accumulation and disrupted lipid turnover. Here, we discuss the biogenesis of LDs, their pathological accumulation in microglia, and the therapeutic potential of targeting LDs. We further propose a hypothetical mechanism by which LDs clearance restore energy metabolism, nuclear transport, facilitate DNA repair, suppress inflammation, and phagocytosis in microglia. Thus, elucidating LDs dynamics in microglia may provide novel therapeutic avenues for modifying the course of NDDs.

Identifiers

PMID41318530
PMCPMC12764834

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.